Are These Fallen Angels Worth Buying At 52-Week Lows: G4S plc, Barclays PLC, Shire PLC And Burberry Group plc

Is it time to buy G4S plc (LON: GFS), Barclays PLC (LON: BARC), Shire PLC (LON: SHP) and Burberry Group plc (LON: BRBY) after recent declines?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Trying to seek out the market’s most undervalued and undiscovered value stocks can be tricky. However, the 52-week low ‘bargain bin’ never fails to throw up some interesting ideas.

So, here are just five former market darlings that have fallen from grace during the past few months and now trade at or near 52-week lows.

China concerns 

Burberry (LSE: BRBY) has crashed to a 52-week low following concerns about the sustainability of the company’s Asian sales. The company warned back in October that due to an “increasingly challenging environment for luxury, particularly Chinese customers” retail sales growth for the year would slow to 2% from 8% reported for the first quarter.

However, even after recent declines Burberry’s shares still look expensive and don’t leave much room for error, so if the company warns on profits again, the shares could drop further. At present, Burberry’s shares are trading at an expensive looking forward P/E of 16.3, although the shares do support a dividend yield of 3%. 

Overpaying?

Shares in Shire (LSE: SHP) printed a new 52-week low this week as reports have started to circulate that the company is considering upping its bid for Baxalta, the US haematology drugmaker. Many investors are concerned that Shire could end up overpaying for Baxalta, especially as Roche, a rival group, recently received approval from the US regulator to allow the testing of a treatment that has the potential to devastate Baxalta’s sales.

Shire’s own shares are hardly cheap. They currently trade at a forward P/E of 18, despite the fact that analysts expect earnings per share to fall 33% this year before rebounding by 12% during 2016. Just like Burberry, it might be wise to stay away from Shire for the time being as there could be further declines to come. 

Not living up to expectations 

G4S’s (LSE: GFS) shares have dropped by 23% this year to a new 52-week and two-year low. Investors have raised many concerns about the state of the company, namely the ability for it to continue to grow internationally, and the state of the group’s balance sheet. In addition to these concerns, G4S’s shares continue to trade at a premium to the wider market. Indeed, the shares currently trade at a forward P/E of 15.8. 

That said, City analysts expect the company’s earnings per share to grow 14% this year. So when factoring in its projected growth rate, G4S’s shares don’t appear to be overly expensive at present levels. Still, the high valuation leaves little room for error if things don’t go to plan. 

No clear strategy

And lastly, 2015 has been yet another year of change for Barclays (LSE: BARC) The bank has re-jigged its restructuring strategy once again, has brought in yet another CEO and continued to sell down assets, but a return to growth has remained elusive. 

Barclays has been floundering for years and has shown time and again that it lacks a coherent strategy. Today the bank has announced that it’s planning to sell all, or part of, its African operations in an attempt to return to growth, although it’s unlikely that this move will be enough to reassure investors. Barclays trades at a forward P/E of 10.6 and the bank’s shares support a yield of 2.9%. 

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended Barclays and Burberry. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »